scispace - formally typeset
Open AccessJournal Article

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

Reads0
Chats0
TLDR
Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients.
About
This article is published in The Lancet.The article was published on 1998-09-12 and is currently open access. It has received 7395 citations till now. The article focuses on the topics: Metformin & Type 2 diabetes.

read more

Citations
More filters
Journal ArticleDOI

Effects of Different Modes of Exercise Training on Glucose Control and Risk Factors for Complications in Type 2 Diabetic Patients: A meta-analysis

TL;DR: All forms of exercise training produce small benefits in the main measure of glucose control: A1C, similar to those of dietary, drug, and insulin treatments.
Journal ArticleDOI

Metformin as a Tool to Target Aging.

TL;DR: Metformin, which has demonstrated protective effects against several age-related diseases in humans, will be tested in the TAME (Targeting Aging with Metformin) trial, as the initial step in the development of increasingly effective next-generation drugs.
Journal ArticleDOI

AMPK, insulin resistance, and the metabolic syndrome.

TL;DR: The hypothesis that dysregulation of AMPK is both a pathogenic factor for metabolic syndrome-related disorders in humans and a target for their prevention and therapy is evaluated.
References
More filters
Journal Article

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

R C Turner, +398 more
- 12 Sep 1998 - 
TL;DR: In this article, the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal Article

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease

TL;DR: Sulfonylurea, metformin, and insulin therapies were similarly effective in improving glucose control compared with a policy of diet therapy and whether any specific therapy is advantageous or disadvantageous.
Journal ArticleDOI

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

TL;DR: The ability of troglitazone to reduce insulin resistance and improves glucose tolerance in obese subjects with either impaired or normal glucose tolerance could be useful in preventing NIDDM.
Journal ArticleDOI

Biguanides and NIDDM

TL;DR: Because metformin does not cause clinical hypoglycemia, it is actually an antihyperglycemic drug that helps combat hypertriglyceridemia, and it has been ascribed some vasoprotective properties.
Journal ArticleDOI

UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.

TL;DR: The UK Prospective Diabetes Study is a multi-centre, prospective, randomised, intervention trial of 5100 newly-diagnosed patients with Type 2 (non-insulin-dependent) diabetes mellitus which aims to determine whether improved blood glucose control will prevent complications and reduce the associated morbidity and mortality.
Related Papers (5)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

R C Turner, +398 more
- 12 Sep 1998 -